Revolutionary mRNA Therapy Offers Hope for Treating Vision Loss and Blinding Conditions
- A recent study from Mass Eye and Ear researchers shows that a new mRNA-based therapy may prevent blindness and scarring from proliferative vitreoretinopathy (PVR).
- Kim, a co-author, stated that this therapy is the first to use mRNA injections directly into the eye.
- PVR is caused by scar tissue forming inside the eye after trauma.
A recent study from Mass Eye and Ear researchers shows that a new mRNA-based therapy may prevent blindness and scarring from proliferative vitreoretinopathy (PVR). PVR often occurs after retinal detachment repair or eye injury. Currently, surgery is the only treatment option for PVR, but it can increase the risk of the condition.
Dr. Leo A. Kim, a co-author, stated that this therapy is the first to use mRNA injections directly into the eye. The team found that this approach could be used without causing significant inflammation. They hope this research can lead to new treatment options for PVR and other eye diseases.
PVR is caused by scar tissue forming inside the eye after trauma. This scar tissue can contract and detach the retina, leading to blindness. The researchers used various models to demonstrate that mRNA therapeutics can be safely applied in the eye.
They focused on targeting RUNX1, a protein related to scar tissue formation. To inhibit RUNX1, they developed an mRNA called RUNX1-Trap. This molecule keeps RUNX1 in the cell’s cytoplasm, preventing it from creating scar tissue. Laboratory tests showed that RUNX1-Trap reduced scar tissue and abnormal blood vessel growth.
This study serves as proof that mRNA technology could be effective in treating PVR and similar eye diseases. However, the research was conducted in cell and animal models, and human testing has not yet occurred. Additionally, mRNA does not stay in cells for long, so the duration of treatment effects and the need for repeated doses remain uncertain.
Arboleda-Velasquez, another researcher, believes targeting RUNX1 could lead to new therapies for sight-threatening conditions. The team also sees potential applications of this technique in other areas of medicine.
William P. Miller, another co-author, remarked on the team’s collaboration across various fields, highlighting the significance of this mRNA technology in ophthalmology and its potential broader medical implications.
Reference:
O’Hare M, Miller WP, Arevalo-Alquichire S, et al. An mRNA-encoded dominant-negative inhibitor of transcription factor RUNX1 suppresses vitreoretinal disease in experimental models. Sci Transl Med. 2024;16(775):eadh0994. doi: 10.1126/scitranslmed.adh0994